BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30097488)

  • 1. Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.
    Namløs HM; Boye K; Mishkin SJ; Barøy T; Lorenz S; Bjerkehagen B; Stratford EW; Munthe E; Kudlow BA; Myklebost O; Meza-Zepeda LA
    Mol Cancer Ther; 2018 Nov; 17(11):2473-2480. PubMed ID: 30097488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
    Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebio A; Virgili AC; Menso MM; Martín-Broto J; Sansó M; García-Valverde A; Rosell J; Fletcher JA; George S; Carles J; Arribas J
    BMC Cancer; 2020 Feb; 20(1):99. PubMed ID: 32024476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST.
    Xu H; Chen L; Shao Y; Zhu D; Zhi X; Zhang Q; Li F; Xu J; Liu X; Xu Z
    Mol Cancer Ther; 2018 Jan; 17(1):290-296. PubMed ID: 29133619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
    Jilg S; Rassner M; Maier J; Waldeck S; Kehl V; Follo M; Philipp U; Sauter A; Specht K; Mitschke J; Lange T; Bauer S; Jost PJ; Peschel C; Duyster J; Gaiser T; Hohenberger P; von Bubnoff N
    Int J Cancer; 2019 Oct; 145(8):2292-2303. PubMed ID: 30882891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring advanced gastrointestinal stromal tumor with circulating tumor DNA.
    Gómez-Peregrina D; Cicala CM; Serrano C
    Curr Opin Oncol; 2024 Jul; 36(4):282-290. PubMed ID: 38726808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
    Wada N; Kurokawa Y; Takahashi T; Hamakawa T; Hirota S; Naka T; Miyazaki Y; Makino T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Oncology; 2016; 90(2):112-7. PubMed ID: 26779618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.
    Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM
    Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor.
    Kang G; Sohn BS; Pyo JS; Kim JY; Lee B; Kim KM
    Mol Diagn Ther; 2016 Aug; 20(4):347-51. PubMed ID: 27178185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies.
    Ko TK; Lee E; Ng CC; Yang VS; Farid M; Teh BT; Chan JY; Somasundaram N
    Front Oncol; 2022; 12():840843. PubMed ID: 35273917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
    Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
    Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA.
    Maier J; Lange T; Kerle I; Specht K; Bruegel M; Wickenhauser C; Jost P; Niederwieser D; Peschel C; Duyster J; von Bubnoff N
    Clin Cancer Res; 2013 Sep; 19(17):4854-67. PubMed ID: 23833305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
    Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
    Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Circulating Tumor DNA During Surgical Treatment in Patients with Gastrointestinal Stromal Tumors.
    Johansson G; Berndsen M; Lindskog S; Österlund T; Fagman H; Muth A; Ståhlberg A
    Mol Cancer Ther; 2021 Dec; 20(12):2568-2576. PubMed ID: 34552011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.
    Hedenström P; Nilsson B; Demir A; Andersson C; Enlund F; Nilsson O; Sadik R
    World J Gastroenterol; 2017 Aug; 23(32):5925-5935. PubMed ID: 28932084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
    Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
    J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.
    Boonstra PA; Ter Elst A; Tibbesma M; Gietema JA; Schuuring E; Reyners AKL
    Oncologist; 2019 Jun; 24(6):e387-e390. PubMed ID: 30670599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.